{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:54:25Z","timestamp":1790949265232,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hepatitis C Virus (HCV) Prevention and Control System Development Project of Pudong New Area, Shanghai","award":["PW2023D-08"],"award-info":[{"award-number":["PW2023D-08"]}]},{"name":"Public Health Discipline Development of Advancing Medical Care through Science and Education in Pudong New Area, Shanghai","award":["PWGw2025-03"],"award-info":[{"award-number":["PWGw2025-03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prevalence of hepatitis C virus (HCV) infection among people who use drugs (PWUD) in China remains high, yet diagnosis and treatment rates are low. Strategies are urgently needed to achieve the World Health Organization\u2019s goal of eliminating HCV as a public health threat by 2030.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To improve HCV diagnosis and treatment rates among PWUD in Pudong New Area, Shanghai, China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A non-randomized controlled intervention study was implemented among individuals with a substance addiction history in Pudong New Area, Shanghai, China. Three models were explored in our study. In the Self-Referral (SR) model, HCV antibody-positive individuals relied on their own initiative to seek medical services. In the Standard Intensive Referral (SIR) model, managerial supervision was strengthened. The Active Intensive Referral (AIR) model placed greater emphasis on managerial proactivity, enhancing screening and treatment for high-risk populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 3926 PWUD from 36 communities in Pudong New Area underwent rapid HCV antibody testing in the SR model. These numbers were 1973 and 191, respectively, in the SIR and AIR models. Only 18.9% population completed HCV RNA testing in the SR model compared with 100.0% in both the SIR and AIR models (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Overall, 70\/146(47.9%) PWUD in the SR model were identified with HCV RNA, consistent with the SIR and AIR models [339\/916(37.0%) and 74\/191(38.7%),\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05]. In terms of treatment, 47\/74(63.5%) of patients in the AIR model initiated treatment, significantly higher than the 15\/70 (21.4%) in the SR model and 73\/339 (21.5%) in the SIR model (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Genotype 3, particularly subtype 3b, was the most prevalent genotype among PWUD in our study, respectively accounting for 23\/38 [60.5%] in the AIR model and 112\/166 [67.5%] in the SIR model. In the AIR model, all participants received a liver stiffness test. Fifty-two (27.2%) patients had a liver stiffness of more than 12.5\u00a0kPa. One hundred and eighty-one persons completed the questionnaire in the AIR model. The results revealed that few people had high educational attainment. More than half (52.5%) of the population had no stable marital relationship.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A multidisciplinary community-based approach significantly improved HCV diagnosis and treatment among PWUD. Despite limitations, the AIR model may represent a promising approach to improving the HCV care cascade among PWUD and could potentially contribute to China\u2019s efforts to optimize cascade management for hepatitis C elimination among specific high-risk populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-026-01498-8","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:37:01Z","timestamp":1783510621000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Community-based interventions for hepatitis C virus elimination among people who use drugs in Shanghai, China"],"prefix":"10.1186","volume":"23","author":[{"given":"Xiaoxiao","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqiu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guichun","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"issue":"6","key":"1498_CR1","first-page":"533","volume":"8","author":"A Artenie","year":"2023","unstructured":"Artenie A, Stone J, Fraser H, et al. Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis. The lancet. Gastroenterol Hepatol. 2023;8(6):533\u201352.","journal-title":"Gastroenterol Hepatol"},{"key":"1498_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.drugpo.2019.05.005","volume":"70","author":"Y Bao","year":"2019","unstructured":"Bao Y, Larney S, Peacock A et al. Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: a systematic review and meta-analysis. Int J Drug Policy. 2019;70: 87\u201393.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"1498_CR3","first-page":"315","volume":"10","author":"A Artenie","year":"2025","unstructured":"Artenie A, Trickey A, Looker KJ, et al. Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis: the lancet. Gastroenterol Hepatol. 2025;10(4):315\u201331.","journal-title":"Gastroenterol Hepatol"},{"issue":"3","key":"1498_CR4","first-page":"153","volume":"3","author":"J Grebely","year":"2018","unstructured":"Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial: the lancet. Gastroenterol Hepatol. 2018;3(3):153\u201361.","journal-title":"Gastroenterol Hepatol"},{"issue":"3","key":"1498_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/jvh.12859","volume":"25","author":"O Falade-Nwulia","year":"2018","unstructured":"Falade-Nwulia O, Sulkowski MS, Merkow A, et al. Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era. J Viral Hepat. 2018;25(3):220\u20137.","journal-title":"J Viral Hepat"},{"issue":"12","key":"1498_CR6","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S1473-3099(16)30325-5","volume":"16","author":"L Degenhardt","year":"2016","unstructured":"Degenhardt L, Charlson F, Stanaway J, et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the global burden of disease study 2013. Lancet Infect Dis. 2016;16(12):1385\u201398.","journal-title":"Lancet Infect Dis"},{"issue":"73","key":"1498_CR7","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"5","author":"F Jean-Michel Pawlotsky","year":"2020","unstructured":"Jean-Michel Pawlotsky F, N A A. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;5(73):1170\u2013218.","journal-title":"J Hepatol"},{"key":"1498_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad319","author":"D Bhattacharya","year":"2023","unstructured":"Bhattacharya D, Aronsohn A, Price J, et al. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis. 2023. https:\/\/doi.org\/10.1093\/cid\/ciad319.","journal-title":"Clin Infect Dis"},{"key":"1498_CR9","unstructured":"Who. Global health sector strategy on viral hepatitis 2016\u20132021. Towards ending viral hepatitis. World Health Organ. 2016 (https:\/\/www.who.int\/publications\/i\/item\/WHO-HIV-2016.06)."},{"key":"1498_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.drugpo.2017.05.033","volume":"47","author":"AA Artenie","year":"2017","unstructured":"Artenie AA, Zang G, Daniel M, et al. Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection. Int J drug policy. 2017;47:239\u201343.","journal-title":"Int J drug policy"},{"issue":"7","key":"1498_CR11","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3390\/v14071555","volume":"14","author":"A Conway","year":"2022","unstructured":"Conway A, Valerio H, Alavi M, et al. A testing campaign intervention consisting of peer-facilitated engagement, point-of-care HCV RNA testing, and linkage to nursing support to enhance hepatitis C treatment uptake among people who inject drugs: the ETHOS engage study. Viruses. 2022;14(7):1555.","journal-title":"Viruses"},{"key":"1498_CR12","first-page":"100801","volume":"37","author":"N Nagot","year":"2023","unstructured":"Nagot N, Binh NT, Hong TT, et al. A community-based strategy to eliminate hepatitis C among people who inject drugs in Vietnam: the Lancet regional health. Western Pac. 2023;37:100801.","journal-title":"Western Pac"},{"issue":"5","key":"1498_CR13","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/phn.13092","volume":"39","author":"M Selfridge","year":"2022","unstructured":"Selfridge M, Barnett T, Lundgren K, et al. Treating people where they are: Nurse-led micro\u2010elimination of hepatitis C in supported housing sites for networks of people who inject drugs in Victoria, Canada. Public Health Nurs. 2022;39(5):1009\u201316.","journal-title":"Public Health Nurs"},{"issue":"6","key":"1498_CR14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.5694\/mja2.51885","volume":"218","author":"MB Macisaac","year":"2023","unstructured":"Macisaac MB, Whitton B, Hubble A, et al. Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility. Med J Aust. 2023;218(6):256\u201361.","journal-title":"Med J Aust"},{"issue":"4","key":"1498_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/aid2.13382","volume":"11","author":"CCPH Fai-Meng Sou","year":"2024","unstructured":"Fai-Meng Sou CCPH. Strategies of hepatitis C virus elimination for people who inject drugs receiving opioid agonist therapy in the era of direct-acting antivirals. Adv Dig Med. 2024;11(4):189\u201395.","journal-title":"Adv Dig Med"},{"key":"1498_CR16","unstructured":"Guideline for the prevention and treatment of hepatitis C. (2022 version). Zhonghua Gan Zang Bing Za Zhi. 2022;30(12):1332\u20131348."},{"key":"1498_CR17","unstructured":"Pan Ling PL. Antiviral treatment for hepatitis C among injecting drug users in the era of direct-acting antiviral agents. Zhong hua gan zang bing za zhi. 2020;28(10):893\u20136."},{"issue":"4","key":"1498_CR18","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s40121-023-00779-0","volume":"12","author":"K Fang","year":"2023","unstructured":"Fang K, Wang H, Lin Y, et al. Modeling the impacts of prevention and treatment interventions on hepatitis C among people who inject drugs in China. Infect Dis therapy. 2023;12(4):1043\u201355.","journal-title":"Infect Dis therapy"},{"issue":"1","key":"1498_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12954-017-0197-3","volume":"14","author":"Z Li","year":"2017","unstructured":"Li Z, Zhang L, Wang J, et al. Hepatitis C infection, related services, and barriers to HCV treatment among drug users in methadone maintenance treatment (MMT) clinics in Shanghai, China. Harm Reduct J. 2017;14(1):71.","journal-title":"Harm Reduct J"},{"issue":"12","key":"1498_CR20","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1111\/jvh.13612","volume":"28","author":"F Djordjevic","year":"2021","unstructured":"Djordjevic F, Ryan K, Gunn J, et al. Health service utilization and experiences of stigma amongst people who inject drugs in Melbourne, Australia. J Viral Hepatitis. 2021;28(12):1738\u201343.","journal-title":"J Viral Hepatitis"},{"issue":"1","key":"1498_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12889-022-12786-w","volume":"22","author":"H Chan","year":"2022","unstructured":"Chan H, Hassali MA, Mohammed NS, et al. Barriers to scaling up hepatitis C treatment in Malaysia: a qualitative study with key stakeholders. BMC Public Health. 2022;22(1):371.","journal-title":"BMC Public Health"},{"issue":"11","key":"1498_CR22","first-page":"2578","volume":"41","author":"BL Draper","year":"2021","unstructured":"Draper BL, Htay H, Pedrana A, et al. Outcomes of the CT2 study: a \u2018one-stop-shop\u2019 for community-based hepatitis C testing and treatment in Yangon, Myanmar. Liver Int official. J Int Association Study Liver. 2021;41(11):2578\u201389.","journal-title":"Liver Int official J Int Association Study Liver"},{"issue":"3","key":"1498_CR23","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jhep.2023.04.019","volume":"79","author":"Y Sheehan","year":"2023","unstructured":"Sheehan Y, Cunningham EB, Cochrane A, et al. A \u2018one-stop-shop\u2019 point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: the PIVOT study. J Hepatol. 2023;79(3):635\u201344.","journal-title":"J Hepatol"},{"issue":"1","key":"1498_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12954-023-00831-9","volume":"20","author":"SN Kapadia","year":"2023","unstructured":"Kapadia SN, Aponte-Melendez Y, Rodriguez A, et al. Treated like a Human Being: perspectives of people who inject drugs attending low-threshold HCV treatment at a syringe service program in New York City. Harm Reduct J. 2023;20(1):10\u201395.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1498_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12954-024-01009-7","volume":"21","author":"E Yela","year":"2024","unstructured":"Yela E, Sol\u00e9 N, Puig L, et al. Barriers to access to hepatitis C treatment with direct-acting antivirals in people who inject drugs in the community setting. Harm Reduct J. 2024;21(1):88.","journal-title":"Harm Reduct J"},{"issue":"6","key":"1498_CR26","first-page":"100481","volume":"4","author":"P Di Carrieri","year":"2022","unstructured":"Carrieri P, Carrat F, Di Beo V, et al. Severe liver fibrosis in the HCV cure era: major effects of social vulnerability, diabetes, and unhealthy behaviors. JHEP Rep Innov Hepatol. 2022;4(6):100481.","journal-title":"JHEP Rep Innov Hepatol"},{"key":"1498_CR27","doi-asserted-by":"publisher","first-page":"104516","DOI":"10.1016\/j.drugpo.2024.104516","volume":"130","author":"Y Sheehan","year":"2024","unstructured":"Sheehan Y, Cochrane A, Treloar C, et al. Understanding hepatitis C virus (HCV) health literacy and educational needs among people in prison to enhance HCV care in prisons. Int J Drug Policy. 2024;130:104516.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1498_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/jmv.25311","volume":"91","author":"G Du","year":"2019","unstructured":"Du G, Li X, Musa TH, et al. The nationwide distribution and trends of hepatitis C virus genotypes in mainland China. J Med Virol. 2019;91(3):401\u201310.","journal-title":"J Med Virol"},{"issue":"1","key":"1498_CR29","doi-asserted-by":"publisher","first-page":"e245288","DOI":"10.1371\/journal.pone.0245288","volume":"16","author":"A Heffernan","year":"2021","unstructured":"Heffernan A, Ma Y, Nayagam S, et al. Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China. PLoS ONE. 2021;16(1):e245288.","journal-title":"PLoS ONE"},{"issue":"3","key":"1498_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/CM9.0000000000000629","volume":"133","author":"N Wu","year":"2020","unstructured":"Wu N, Rao H, Yang W, et al. Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohort. Chin Med J (Engl). 2020;133(3):253\u201361.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"1498_CR31","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12967-019-2033-x","volume":"17","author":"L Rinaldi","year":"2019","unstructured":"Rinaldi L, Perrella A, Guarino M, et al. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. J translational Med. 2019;17(1):292.","journal-title":"J translational Med"},{"issue":"6","key":"1498_CR32","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.jhep.2020.08.006","volume":"73","author":"V Calvaruso","year":"2020","unstructured":"Calvaruso V, Crax\u00ec A. Hepatic benefits of HCV cure. J Hepatol. 2020;73(6):1548\u201356.","journal-title":"J Hepatol"},{"issue":"1","key":"1498_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13012-019-0861-y","volume":"14","author":"EN Woodward","year":"2019","unstructured":"Woodward EN, Matthieu MM, Uchendu US, et al. The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment. Implement science: IS. 2019;14(1):26.","journal-title":"Implement science: IS"},{"issue":"5","key":"1498_CR34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/jvh.13664","volume":"29","author":"J Howell","year":"2022","unstructured":"Howell J, Traeger MW, Williams B, et al. The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: an Australian pilot study. J Viral Hepatitis. 2022;29(5):375\u201384.","journal-title":"J Viral Hepatitis"},{"issue":"1","key":"1498_CR35","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12954-024-01119-2","volume":"21","author":"G Steffen","year":"2024","unstructured":"Steffen G, Krings A, Guttmann S, et al. Progress and challenges in the elimination of hepatitis C among people who inject drugs in Germany: results of a pilot study for a national monitoring system, 10 years after the first data collection. Harm Reduct J. 2024;21(1):222.","journal-title":"Harm Reduct J"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-026-01498-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01498-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01498-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:02:42Z","timestamp":1790946162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-026-01498-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1498"],"URL":"https:\/\/doi.org\/10.1186\/s12954-026-01498-8","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We confirm that this manuscript represents the author\u2019s original work and has not been published previously in any form or language. The manuscript is not currently under consideration by any other journal, and all authors approve its submission to this journal.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"157"}}